Sadiq Duaa Raad, Mikhael Ehab Mudher
Department of Clinical Pharmacy, University of Babylon, College of Pharmacy, Hillah, Iraq.
Department of Clinical Pharmacy, University of Baghdad, College of Pharmacy, Baghdad, Iraq.
Clin Ophthalmol. 2024 Jul 17;18:2107-2112. doi: 10.2147/OPTH.S478850. eCollection 2024.
Glaucoma is a chronic progressive eye disorder. It is the primary cause of blindness. To prevent glaucomatous damage and blindness, the intra-ocular pressure (IOP) must be lowered to certain levels, this level is known as "IOP" target. Many studies conducted in developed countries have found that the majority of glaucoma patients failed to reach their target IOP.
This study aimed to assess the achievement of IOP target among Iraqi patients with glaucoma and to determine the factors affecting it.
A single-center retrospective cohort study was conducted by inspecting the records of all patients with confirmed cases of glaucoma who were admitted to the Ibn-Al-Haitham Hospital outpatient unit from January 2020 to December 2022. To be included in the study, the patient must be newly diagnosed with glaucoma. In addition, full information on the patient's demographics, medical therapy used, and IOP at baseline and after 1 month of treatment must be available in the patient's case sheet. After considering the study inclusion criteria, the records of 760 patients were excluded, and only 100 patients were eligible.
The included patients were mostly males, with an average age of 57.86 years. A 70% of the patients had elevated IOP in both eyes. Most patients (38%) were treated with two anti-glaucoma drugs. Only 35% of the patients achieved their targeted IOP. Regarding the factors influencing the achievement of the IOP target, all demographic data (age and gender) had a non-significant effect, while the number of prescribed drugs affected the ability of the patient to reach the IOP target.
Most of Iraqi glaucomatous patients do not achieve their IOP target. The number of prescribed eye drops can significantly affect the ability of glaucoma patients to reach their targeted IOP.
青光眼是一种慢性进行性眼病。它是失明的主要原因。为了预防青光眼性损害和失明，眼内压（IOP）必须降低到一定水平，这个水平被称为“IOP”目标。在发达国家进行的许多研究发现，大多数青光眼患者未能达到其IOP目标。
本研究旨在评估伊拉克青光眼患者IOP目标的达成情况，并确定影响该目标达成的因素。
通过查阅2020年1月至2022年12月入住伊本·海赛姆医院门诊的所有确诊青光眼患者的记录，进行了一项单中心回顾性队列研究。要纳入该研究，患者必须是新诊断为青光眼。此外，患者病历中必须有关于患者人口统计学、使用的药物治疗以及基线和治疗1个月后的IOP的完整信息。在考虑研究纳入标准后，排除了760例患者的记录，只有100例患者符合条件。
纳入的患者大多为男性，平均年龄为57.86岁。70%的患者双眼IOP升高。大多数患者（38%）接受了两种抗青光眼药物治疗。只有35%的患者达到了他们的目标IOP。关于影响IOP目标达成的因素，所有人口统计学数据（年龄和性别）的影响均不显著，而所开药物的数量影响患者达到IOP目标的能力。
大多数伊拉克青光眼患者未达到其IOP目标。所开眼药水的数量可显著影响青光眼患者达到其目标IOP的能力。
